Objective:To investigate serum levels of homocysteine (HCY) and glial fibrillary acidic protein (GFAP) in patients with acute cerebral infarction (ACI) and its clinical significance. Methods:Serum HCY and GFAP levels were measured by enzyme-linked immunosorbent assay (ELISA) in 92 patients with ACI and40 patients with non-ACI were included in the control group. The subjects were grouped with the National Institutes of Health Stroke Scale (NIHSS) score, onset time and infarct size. The differences in serum HCY and GFAP levels in different groups were analyzed. The receiver operating characteristic (ROC) curve was constructed to obtain the positive and negative threshold values and diagnostic sensitivity and specificity of HCY and GFAP in the diagnosis of cerebral infarction. Results:The levels of HCY and GFAP in ACI patients were (18.26±5.37) μmol·L-1 and (1.28±0.64) μg·L-1, which were significantly higher than those in the control group (P<0.01). The serum HCY level in the 12-24 h group was higher than the <12 h group (P<0.05). The expression of serum HCY and GFAP was the lowest in the small area infarction (SI) group and the highest in the large area infarction (LI) group, the difference was statistically significant (P<0.01). The NIHSS score <4 group had the lowest HCY and GFAP levels, and the NIHSS sore>15 group was the highest, the difference was statistically significant (P<0.01). There was a positive correlation between serum HCY and GFAPlevels (r=0.514, P=0.001). HCY was positively correlated with hypertension, onset time, infarct size, and NIHSS score. GFAP was positively correlated with hypertension, infarct size, and NIHSS score. Logistic regression analysis found that hypertension, infarct size, and NIHSS score were independent risk factors for serum HCY and GFAP expression levels. ROC analysis showed that the best cutoff value of HCI and GFAP for diagnosis of ACI were 15.03 μmol·L-1, 1.02 μg·L-1. Conclusion:The levels of serum HCY and GFAP in the patients with ACI are significantly increased, and have a certain correlation with the severity of ACI, which can provide a basis for early diagnosis and treatment of ACI. |
[1] 陈静,白宏英.早期进展性脑梗死治疗的临床观察[J].中国实用神经疾病杂志,2016,18(10):261-262.
[2] 许琳,杜肖彦.急性脑梗死病人血浆同型半胱氨酸、超敏C反应蛋白、D-二聚体、脂蛋白α水平的改变及临床意义[J].内蒙古医科大学学报,2017,39(3):232-235.
[3] ZHAO L,HU F X.Lipoic acid treatment of aged type 2 diabetes mellitus complicated with acute cerebral infarction[J].Eur Rev Med Pharmacol,2014,18(23):3715-3719.
[4] 程明,王跃.重复经颅磁刺激联合丁苯酞对脑卒中后运动功能恢复及血清学指标的影响[J].东南大学学报(医学版),2017,36(6):946-950.
[5] CAMERLINGO M,TUDOSE V,TOGNOZZI M,et al.Predictors of recanalisation in acute cerebral infarction from occlusion of the terminal internal carotid artery or of the middle cerebral artery mainstem treated with thrombolysis[J].Int J Neurosci,2014,124(3):199-203.
[6] 吴乐怀.血清同型半胱氨酸水平与急性脑梗死相关性分析[J].中国医药科学,2016,6(23):198-201.
[7] 冯昌允,戴秀华,董琰.惊厥患儿血清中GFAP及MBP的表达水平及临床意义[J].中国煤炭工业医学杂志,2016,19(2):201-204.
[8] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华全科神经科杂志,2015,48(4):246-257.
[9] 史哲,吴永辉,王拥军,等.血清同型半胱氨酸水平与急性脑梗死严重程度及中国缺血性卒中亚型分型的关系[J].中国动脉硬化杂志,2012,20(9):846-848.
[10] 胡重灵,杨新玲,毛德强,等.急性脑梗死患者血清泛素羧基末端水解酶-1和胶质纤维酸性蛋白的表达及其临床意义[J].中南大学学报(医学版),2017,42(3):284-290.
[11] 王晶,刘家丰,郭兆慧,等.高同型半胱氨酸血症与老年急性脑梗死预后的关系研究[J].中华高血压杂志,2013,15(11):599-601.
[12] 辛永飞,王珩.血清同型半胱氨酸与短暂性脑缺血发作及预后的相关性研究[J].中国中西医结合急救杂志,2016,23(2):172-174.
[13] 朱勇冬.血清胱抑素C、基质金属蛋白酶-9及同型半胱氨酸与脑梗死关系的研究[J].国际神经病学神经外科学杂志,2016,43(3):233-236.
[14] BROUNS R,De VIL B,CRAS P,et al.Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic storke patients[J].Clin Chem,2010,56(3):451-458.
[15] 周静,罗勇,姚珊,等.急性缺血性脑卒中患者血清HCY、GDF-15、GFAP水平与神经功能及预后的关系[J].山东医药,2017,57(18):46-48.
[16] 李娜,任长虹,吉训明.脑梗死患者急性期血清泛素羧基末端水解酶-1及神经胶质原纤维酸性蛋白水平的变化[J].中国脑血管病杂志,2016,13(7):337-342. |